Associate, Process Development (Cells

We are seeking a highly enthusiastic Associate, Process Development (Cells) to join our process development team focused on developing bioprinted tissue therapeutics for cell therapy applications. You will support the production, qualification, and scale-up of multiple cell lines to drive the development of bioprinted tissue therapeutics (BTT). You’ll be joining a company committed to developing regenerative medicines that deliver life-changing, functional cures for patients living with serious diseases.

• Independently support the production and supply of various cell types to Aspect’s CMC and R&D groups for downstream bioprinting and assay development.
• Independently complete all stages of cell culture processing including thawing, expansion, media change, aggregation, cryopreservation, and banking.
• Assess and interpret in vitro viability and functional assays for cell characterization.
• Optimize and contribute to the scale-up processing of therapeutic cells.
• Contribute to the development of release Certificate of Analysis (CoA) for internal cell lines to document post-production characterization and ensure quality cell products.
• Complete internal IQ/OQ/PQ of new cell processing and manufacturing equipment.
• Work closely with R&D, CMC, quality, and regulatory teams to support non-GMP technology transfer(s) of culture processes in compliance with regulatory requirements.
• Perform data collection and analysis to contribute insights for cell culture process improvement.
  
  Assist with reagents and buffers preparation, and complete periodic inventory checks.
• Collaborate with cross functional teams (preclinical R&D, CMC, Therapeutic Cell Platforms) to refine bioprocessing methods.
• Create, review, and maintain documentation such as standard operating procedures (SOPs), Batch Production Records (BPRs), protocols, reagent preparation forms, and experimental reports in Good Documentation Practices (GDP).
• Develop subject matter expertise and work with other CMC teams to ensure technical compliance and adherence.

• Education +
  
  Experience:
  
  BSc (with 2+ years of experience) or MSc in Cell Biology, Biotechnology, Biomedical Engineering, or a related field with demonstrated experience working aseptically with mammalian cell culture preferably in an industry setting.
• Knowledge: Experience with immortalized insulinoma cell lines, primary or stem cell derived insulin-producing cells will be an asset.
• Go-Getter: You work with a sense of urgency, are results-driven, and thrive in a fast-paced, interdisciplinary, and entrepreneurial environment. You are willing to roll up your sleeves and do what it takes to get the job done.
• Collaborative: You thrive in a multi-disciplinary team environment and believe that we can get further, faster by working together. You take direction well and ask for clarification when necessary.
• Effective Communicator: You are an active listener who can communicate to different audiences in diverse situations.

The hiring range for this role is $64,000 - $72,000, annually. Our ranges are based on market data. Offered salaries will be based on a combination of factors including, but not limited to, job-related knowledge, skills, education, and experience. For candidates who exceed role requirements, we are open to exploring above-range offers. Note that base salary is just one part of the overall compensation bers of the Aspect team also receive a comprehensive benefits package, and support for continuous learning and career progression.

Aspect Biosystems is a biotechnology company pioneering the development of a novel category of regenerative medicine designed to restore or supplement biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials.

Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine…